| |
NEXMED CONFIRMS PUBLICATION ON ANTI-FUNGAL PRODUCT
East Windsor, NJ, June 3, 2008 -- NexMed, Inc. (Nasdaq: NEXM), a developer of innovative products based on the NexACT® drug delivery technology, today confirmed that an article on its topical treatment for onychomycosis (nail fungus) licensed to Novartis, was published in the May 2008 issue of Mycoses. The article is entitled, “Determination of the Efficacy of Terbinafine HCl Nail Solution in the Topical Treatment of Dermatophytosis in a Guinea Pig Model.” Mycoses is an international journal that publishes articles on topics concerning medical or veterinary mycology. A copy of the article is available by request to NexMed.
NM100060 is a topical application of Lamisil® (terbinafine hydrochloride), formulated with terbinafine and NexMed’s patented NexACT technology that is being developed for the treatment of onychomycosis. NexMed entered into an exclusive, worldwide agreement with Novartis in September 2005, under which Novartis assumed all clinical development, regulatory, manufacturing and commercialization responsibilities for NM100060.
About NexMed
NexMed, Inc. is leveraging its proprietary NexACT drug delivery technology to develop innovative topical pharmaceutical products that address unmet medical needs. NM100060 is currently in pivotal Phase 3 trials in the U.S. and Europe. In November 2007, NexMed’s New Drug Application for its alprostadil treatment for erectile dysfunction was accepted for review by the FDA and the Company signed a U.S. licensing agreement for the product with Warner Chilcott. The Company’s New Drug Submission for the product was accepted for review by Health Canada in February 2008. NexMed's pipeline also includes a Phase 2 treatment for female sexual arousal disorder and an early stage treatment for psoriasis. For further information about NexMed, go to www.nexmed.com.
Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described, including, but not limited to, obtaining regulatory approval for its products under development, entering into partnering agreements, pursuing growth opportunities, and/or other factors, some of which are outside the control of the Company.
# # #
Company Contact:
Mark Westgate, CFO
NexMed, Inc.
(609) 371-8123, ext: 159
mwestgate@nexmed.com
Investor Relations:
Paula Schwartz
Rx Communications Group, LLC
(917) 322-2216
pschwartz@rxir.com
|
|
